Navigation Links
Common Heart Drug Linked to Cancer Risk in Study
Date:4/8/2013

By Steven Reinberg
HealthDay Reporter

MONDAY, April 8 (HealthDay News) -- A drug called amiodarone that's widely used to treat heartbeat irregularities might raise a patient's risk of cancer, Taiwanese researchers report.

The risk, which the researchers termed "borderline significantly increased," is more pronounced in men and patients who take high doses of the drug, according to the study, which was published online April 8 in the journal Cancer.

"When prescribing amiodarone, doctors need to keep in mind that this medication may increase cancer risk," said lead author Dr. Vincent Yi-Fong Su, from the Taipei Veterans General Hospital. "We suggest that cancer events should be routinely reported in future amiodarone trials, and further observational research is necessary."

Patients taking the drug, however, shouldn't fear they'll get cancer, one expert said.

"Amiodarone is among the most effective antiarrhythmic medications available," said Dr. Gregg Fonarow, a spokesman for the American Heart Association and professor of cardiology at the University of California, Los Angeles. "Well-controlled clinical trials have not demonstrated a significant increase in cancer with use of this medication."

The current study, called an observational study, doesn't prove that amiodarone causes cancer, only that an association was found between people taking the drug and cancer.

Many risk factors for heart disease and arrhythmia are also risk factors for cancer, Fonarow said. The findings of this study comparing those treated with amiodarone to the general population are most likely explained by selection of patients and other factors that weren't taken into account, he said.

"These findings should not be a concern to patients taking amiodarone," Fonarow said.

Amiodarone (sold as Cordarone and Pacerone) is commonly prescribed to prevent life-threatening arrhythmias, such as ventricular tachycardia or ventricular fibrillation, both of which can lead to cardiac arrest.

Ventricular tachycardia is a very rapid beating of the upper chambers of the heart. When these chambers don't beat in the correct order, the condition is called ventricular fibrillation. These problems prevent blood from being pumped properly and can cause the heart to stop beating altogether.

Amiodarone breaks down slowly, so large amounts can remain in soft tissues when the drug is taken for a long time. This might explain its association with cancer, the researchers said. Earlier studies have shown an association between amiodarone and cancer risk, but this is the largest study to date to show a link, they noted.

For the study, Su's team followed more than 6,400 patients taking amiodarone for almost three years. Among these patients, 280 developed cancer.

Men taking high doses of the drug had a 46 percent higher chance of developing cancer than those who were neither male nor taking large doses. Anyone taking high doses had nearly twice the risk of cancer compared with people taking low doses, the researchers found.

Cancers of the digestive system, lung, liver, colon, ovaries and prostate were among the cancers associated with amiodarone, the researchers said.

More information

For more information on amiodarone, visit the U.S. National Library of Medicine.

SOURCES: Vincent Yi-Fong Su, M.D., Taipei Veterans General Hospital, Taiwan; Gregg Fonarow, M.D., spokesman, American Heart Association, and professor, cardiology, University of California, Los Angeles; April 8, 2013, Cancer


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Common Asphalt Sealant May Raise Cancer Risks
2. Life Extension Foundation Seeks Volunteers with Alzheimer's to Participate in a Clinical Trial Utilizing a Common Arthritis Drug
3. LSUHSC research discoveries shed light on common STI
4. Researchers are first to use common virus to fortify adult stem cells
5. Common gene variants explain 42 percent of antidepressant response
6. Paranoia Common After Mugging, Study Says
7. Hospital remains most common place of death for cancer patients in England
8. Commonly used cholesterol calculation underestimates heart disease danger for many
9. Michigan hospitals national leaders in preventing common and costly urinary tract infections
10. How common is The John Next Door?
11. Complications More Common Than Thought for Type of Hip Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common Heart Drug Linked to Cancer Risk in Study
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... 12, 2017 , ... HMP , a leader in healthcare events and ... Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie ... annual award competition recognizes editorial and design excellence across a range of sectors. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology: